In a report released today, Matthew Caufield from H.C. Wainwright reiterated a Buy rating on Ocuphire Pharma (OCUP – Research Report), with a price target of $26.00. The company's shares closed last Thursday at $4.17. Caufield has an average return of 17.2% when recommending Ocuphire Pharma. According to TipRanks.com, Caufield is ranked #3441 out of 7927 analysts. Currently, the analyst consensus on Ocuphire Pharma is a Moderate Buy with an average price target of $26.00. See the top stocks recommended by analysts >> Based on Ocuphire Pharma's latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $489K and GAAP net loss of $4.
https://www.tipranks.com/news/blurbs/ocuphire-pharma-ocup-gets-a-buy-rating-from-h-c-wainwright?utm_source=advfn.com&utm_medium=referral